To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Telbivudine
Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.[1][2][3] Additional recommended knowledgeTelbivudine is a synthetic thymidine nucleoside analogue; it is the L-isomer of thymidine. It is taken once daily. References
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Telbivudine". A list of authors is available in Wikipedia. |
- Category:GTP-Binding_Protein_Regulators
- Toward new solar cells with active learning - To deal with the myriad of possibilities for candidate molecules, the machine decides for itself which data it needs
- Category:EC_1.3.99
- Butabarbital
- Avantes has expanded the world-wide Sales and Service network with a new subsidiary: Avantes China